Tweet

Share with your friends

Close

Identifying oversold tax-loss selling stocks investors are targeting

Identifying oversold tax-loss selling stocks investors are targeting

Published on: | by

There is always plenty of focus on tax loss selling as June 30 approaches. The stocks that have been sold down heavily throughout the year fear an avalanche of selling from investors looking to realise a loss in the current financial year to minimise taxable income.

Ironically, tax loss selling can be at its worst when market conditions are buoyant because investors are looking to offset capital gains that they have locked in on stocks sold throughout the financial year.

However, from a stock-pickers perspective it is worth focusing on buying activity immediately after June 30. At this point, selling has dissipated and savvy investors looking to target stocks deemed to be oversold will come wading in.

However it should be noted that investors should still remain cautious when considering what stocks to invest in at this time and that share trading patterns should not be used as the basis for an investment as they may or may not be replicated. Those considering the stocks in this article should seek independent financial advice.

oversold tax-loss stocks

Even after the first week of the new financial year you will find there are some stocks that are experiencing notable share price accretion. Stocks of all sizes in any sectors can be affected by this trend.

The following chart demonstrates a classic dump and run in June with Lithium Australia’s (ASX: LIT) shares plunging approximately 30% from 10.5 cents to a 12 month low of 7.3 cents.

By contrast, the company’s shares closed at 11 cents, a gain of about 50% after the first week of the new financial year. As can be seen in the chart, they have gone on to increase more than 50% this week under high volumes, hitting an intraday high of 17.5 cents on July 11.

Lithium australia stock price

The past performance of this product is not and should not be taken as an indication of future performance. Caution should be exercised in assessing past performance. This product, like all other financial products, is subject to market forces and unpredictable events that may adversely affect future performance.

Comparing rerated share prices with consensus price targets provides perspective

Finfeed.com has identified five stocks with similar trading patterns that have market capitalisations in a range between $50 million and $1 billion. However, we have added an extra layer to our stock selection process, limiting our universe to companies that have broker coverage, albeit in some cases fairly minimal.

By doing this we have been able to weigh up the difference between the rerated share prices and what could be deemed as fair value. This will assist in determining whether a stock has rebounded too sharply, perhaps helping to avoid those companies that have run ahead of themselves.

The data relates to share price movements between close of business on Friday, June 30 and Friday, June 7 inclusive. Share price increases across the five stocks range from 16% to 26.8%, while discounts to consensus forecasts range from 26% to 37%. Both percentage share price changes and discounts to consensus price targets were effective as at July 7, 2017.

Fluctuations are shown below with the charts dated as at close of business on Wednesday, July 12, allowing you to gain a feel for current momentum.

In examining the companies we have referred to, we have outlined some of the catalysts that have impacted the stocks throughout recent months, as well as pointing to upcoming events that could provide either positive or negative share price momentum.

Galaxy Resources – 33.5% share price gain in week one fiscal FY18

     33.8% discount to consensus 12 month price target

galaxy resources stock price

The past performance of this product is not and should not be taken as an indication of future performance. Caution should be exercised in assessing past performance. This product, like all other financial products, is subject to market forces and unpredictable events that may adversely affect future performance.

Galaxy Resources (ASX: GXY) has hard rock mines and brine assets in Australia, Canada and Argentina. However, what sets it apart from many other early stage players in the popular lithium sector is that it is in the production stage with its Mt Cattlin mine in Ravensthorpe, Western Australia producing 14,038 dry metric tonnes of lithium concentrate in June.

Much of the gloss came off the lithium sector in 2017 as investors chased other in vogue materials such as cobalt. Also, both early stage companies and investors began to acknowledge that the sector was to a large extent running on hype and that many so-called potential projects wouldn’t even get off the ground, let alone come into production.

However, that can’t be said of GXY which received payment for its third shipment of lithium concentrate at the end of June, and based on the revised 2017 contract pricing, achieved US$860 per tonne F.O.B. for this shipment.

Mt Cattlin project

The company has now booked the next three vessels for departure from Esperance, Western Australia with the next vessel currently expected to arrive around mid-July.

Production figures were announced on July 6, and these assisted in providing share price momentum in the latter stages of the week under examination.

One of the most impressive features of the production announcement was the fact that recoveries of 61.3% well exceeded the initial targets in a range between 50% and 55%.

In addition to improvements in the processing facility, crushing operations have continued to improve with approximately 133,000 tonnes of ore crushed during the month of June, the equivalent rate of 1.6 million tonnes per annum throughput.

Given that GXY was producing lithium concentrate at a rate of between 500 and 600 dry metric tonnes during the June period there is the potential for monthly production to increase in the near term. This could be a potential positive share price catalyst.

Shine Corporate – 23.6% share price gain in week one fiscal 2018

      33.6% discount to consensus 12 month price target

shine corporate share price

The past performance of this product is not and should not be taken as an indication of future performance. Caution should be exercised in assessing past performance. This product, like all other financial products, is subject to market forces and unpredictable events that may adversely affect future performance.

As if Slater and Gordon (ASX: SGH) didn’t put enough pressure on the legal sector with its poor performance and questionable disclosure, Shine Corporate (ASX: SHJ) was affected in a similar way in September 2016 after disappointing the market with its financial performance.

On September 22 management announced that there was a potential class action against the company relating to its revised EBITDA guidance issued on January 29, 2016. From this point onwards its share price began to unravel as can be seen in the chart above, falling from $1.16 to a 12 month low of 45 cents in mid-June.

While its share price recovery started a few days prior to the end of fiscal 2017, the high volume buying occurred on Tuesday July 4. This propelled the company’s share price to an intraday high of 68.5 cents, and while it retraced some 10% this week, it is still trading approximately 40% higher than its June low.

Though the bottom line result for the first half of fiscal 2017 was below expectations, the company’s performance was impacted by the recognition of provisions against work in progress and a goodwill impairment relating to the group’s Energy and Resources practice.

Management confirmed in February that SHJ was on track to achieve the bottom end of full year EBITDA guidance which is in a range between $36 million and $40 million. Achievement of this guidance could be seen as the first step towards restoring credibility, and as such may provide positive share price momentum.

FY17 full year EBITDA

Analysts at Morgans CIMB are forecasting a net profit just shy of $20 million, representing earnings per share of 11 cents. This is in line with guidance and implies a conservative PE multiple of 6.2 relative to Friday’s closing price of 68 cents.

The broker’s price target of $1.05 (lowered from $1.21 following SHJ’s interim result) is broadly in line with consensus of $1.02.

dorsaVi – 19% share price gain in week one fiscal 2018

 33% discount to consensus 12 month price target

dorsaVI stock price

The past performance of this product is not and should not be taken as an indication of future performance. Caution should be exercised in assessing past performance. This product, like all other financial products, is subject to market forces and unpredictable events that may adversely affect future performance.

 

dorsaVi (ASX: DVL) develops innovative motion analysis device technologies for use in elite sports, Occupational Health & Safety and clinical applications. The company sees its wearable sensor technology devices, which cover many aspects of detailed human movement in both real-time and real situations, as for the first time providing accurate information outside a biomechanics laboratory.

The company’s ViMove and ViPerform technologies cover the clinical and elite sports sectors respectively, while among other abilities ViSafe has the capacity to enable employers to assess risk of injury for employees as well as test the effectiveness of proposed changes to workplace design, equipment or methods based on objective evidence.

It has been used by major corporations including Crown Resorts, Caterpillar (US), Monash Health, Toyota, BHP Billiton and various retail groups such as Coles and Woolworths.

dorsaVI company timeline

The company recently announced that ViMove was being used to assess the impact on movement and muscle activity of an over-the-counter product in a Pfizer supported study. Commenting on this development, DVL’s Chief Executive, Doctor Andrew Ronchi said, “The importance of using a FDA cleared device to capture clinically relevant data is being recognised by both pharmaceutical and medical device companies”.

Apart from the current study, several medical device companies are using ViMove to investigate the functional outcomes their products have on patients. The technology is particularly useful in this environment as it measures performance before and after treatments or procedures to objectively track improvement.

The product that can potentially improve workplace productivity and benefit regulatory bodies, as well as providing useful data for the likes of insurers. As such, it could well prove to be a technology that many companies see as a necessity rather than a discretionary investment.

Bell Potter analyst, Jon Hester initiated coverage of the stock in March with a buy recommendation and a valuation of 63 cents. While the current consensus share price target of 52 cents sits below the valuation, Friday’s closing price of 34.5 cents still implies a discount of circa 33% to the target price.

The most likely share price catalysts are new contract wins.

Xenith IP Group – 16.6% share price gain in week one fiscal 2018

                                                                        26.3% discount to consensus 12 month share price target

xenith IP group stock price

The past performance of this product is not and should not be taken as an indication of future performance. Caution should be exercised in assessing past performance. This product, like all other financial products, is subject to market forces and unpredictable events that may adversely affect future performance.

Xenith IP Group (ASX: XIP) got off to a flying start after listing on the ASX in November 2015 with its shares increasing circa 30% in the six months to May 2016. However, the intellectual property services group has arguably suffered from growing pains over the last 12 months as the integration of acquisitions impacted the company operationally and financially.

While management appeared justified in claiming the acquisitions of Watermark and Griffith Hack were ‘strategically transformational’, their integration placed a drain on resources and from a financial perspective, negatively impacted earnings as a result of substantial one-off transaction costs.

The acquisitions were funded through the issue of shares which placed a drag on earnings per share, and resulted in a lower than expected interim dividend for the six months to December 31, 2016.

Notwithstanding these developments, the company’s outlook appears bright as it operates in a niche sector with reasonably high barriers to entry. The group’s core business is to provide a comprehensive range of IP services including identification, registration, management, valuation, commercialisation and enforcement of IP rights.

Australia's leading specialist IP groups

XIP has a diversified global client base including Fortune Global 500 companies, multinationals, government instrumentalities and small to medium enterprises.

It is a scalable business model with substantial scope for operational efficiencies through improved utilisation, shared services and integration of technology platforms. One would expect management will have a better understanding of the challenges it faces when integrating new businesses in the future.

Consequently, as XIP expands in Australia through industry consolidation and continues to grow its presence in South-East Asian regions including China, the company should generate robust sales and profit growth.

Analysts at Morgans CIMB are forecasting operating EBITDA to increase from $16.2 million in fiscal 2017 to $28.6 million in fiscal 2018, suggesting XIP could be a stock for forward-looking investors interested in turnaround prospects.

The substantial share price spike in the first week of July occurred under the second-highest trading volumes experienced in the last 12 months. XIP will deliver its full-year result in August when there should be sufficient evidence to indicate where the company is at with integrating acquisitions.

If XIP is back on track, investors will likely view the recent issues as a ‘short-term pain for long-term gain’ sacrifice. As such, August could be an important turning point for the company.

Altura Mining – 16% share price gain in week one fiscal 2018

                                                                          40% discount to consensus 12 month share price target

altura mining stock price

The past performance of this product is not and should not be taken as an indication of future performance. Caution should be exercised in assessing past performance. This product, like all other financial products, is subject to market forces and unpredictable events that may adversely affect future performance.

Altura Mining (ASX: AJM) is another lithium revival story, and one that could continue to run on the back of developments at its world-class Pilgangoora lithium project. Once again, the difference between it and many other early stage hopefuls is that it has a clear path to near term production and profitability with offtake agreements providing income predictability.

As can be seen from the above chart, the company’s share price has continued to run post the first week of fiscal 2018 when it increased from 12.5 cents to 14.5 cents. Wednesday’s closing price of 16 cents implies a share price gain of nearly 30% relative to the June 30 closing price.

AJM’s fortunes received a further boost at the start of the week when it announced that leading Chinese battery manufacturer J&R Optimum Energy (AJM’s largest shareholder) would receive a minimum of 100,000 tonnes of 6% grade spodumene concentrate on an annual basis.

AJM also noted that an updated offtake agreement with Lionergy would also account for annual supply of 100,000 tonnes. Also of significance is the fact that the company has agreed on both floor and ceiling prices which will guarantee strong positive financial returns from the Pilgangoora lithium project.

Altura Pilgangoora lithium project results

Management confirmed that development remained on track for commissioning in the first quarter of 2018 and that its plans for funding stage II of the project which would ramp up annual production to 450,000 tonnes were proceeding as expected.

The entrance of another offtake partner which sees the best part of early stage production now covered should provide AJM with a sound platform to negotiate funding.

Analysts at Beer & Co Equity Research anticipate funding will be completed by August, and the broker is of the view that meeting this milestone will create positive share price momentum.

Beer & Co is forecasting AJM to deliver a maiden net profit of $10 million in fiscal 2018, increasing to $75 million in fiscal 2019. This currently represents earnings per share (EPS) of 5.1 cents, however there is likely to be some EPS dilution if the company issues new shares as part of its funding arrangement.

It is worth noting though that even if the issue of new shares diluted earnings per share by circa 20%, the company would be trading on a conservative forward PE multiple of approximately four relative to its current trading range.

Consequently, the consensus 12-month price target of 23 cents appears to be within AJM’s reach, particularly once funding is ratified and there is better clarity around the group’s earnings outlook.

This article is General Information and contains only some information about some elements of one or more financial products. It may contain; (1) broker projections and price targets that are only estimates and may not be met, (2) historical data in terms of earnings performance and/or share trading patterns that should not be used as the basis for an investment as they may or may not be replicated. Those considering engaging with any financial product mentioned in this article should always seek independent financial advice from a licensed financial advisor before making any financial decisions.

Sign up for the newsletter Sign up for the newsletter
[gravityform id="5" name="OM Subscribe Form" title="false" description="false" ajax="true"]
  • This field is for validation purposes and should be left unchanged.
[gravityform id="5" name="OM Subscribe Form" title="false" description="false" ajax="true"]
  • This field is for validation purposes and should be left unchanged.
[gravityform id="3" name="OM Popup Form" title="false" description="false" ajax="true"]
  • This field is for validation purposes and should be left unchanged.
[gravityform id="3" name="OM Popup Form" title="false" description="false" ajax="true"]
  • This field is for validation purposes and should be left unchanged.